Effectiveness and safety of rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and heart failure

被引：0
|
作者：
Coleman, C. I. [1 ]
Baker, W. L. [1 ]
Bunz, T. J. [2 ]
Eriksson, D. [3 ]
Meinecke, A. K. [3 ]
Sood, N. A. [4 ]
机构：
[1] Univ Connecticut, Pharm Practice, Storrs, CT USA
[2] New England Hlth Analyt LLC, Pharmacoepidemiol, Granby, CO USA
[3] Bayer AG, Berlin, Germany
[4] Southcoast Hlth Syst, Cardiac Electrophysiol, Fall River, MA USA
来源：
EUROPEAN HEART JOURNAL | 2018年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P4813
引用
收藏
页码：1012 / 1012
页数：1
相关论文
共 50 条
  • [1] Influence of Polypharmacy on the Effectiveness and Safety of Rivaroxaban versus Warfarin in Patients With Nonvalvular Atrial Fibrillation
    Coleman, Craig, I
    Martinez, Brandon K.
    Bunz, Thomas J.
    Eriksson, Daniel
    Meinecke, Anna-Katharina
    Sood, Nitesh
    Baker, William L.
    CIRCULATION, 2018, 138
  • [2] Influence of Polypharmacy on the Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation
    Martinez, Brandon K.
    Baker, William L.
    Sood, Nitesh A.
    Bunz, Thomas J.
    Meinecke, Anna-Katharina
    Eriksson, Daniel
    Coleman, Craig, I
    PHARMACOTHERAPY, 2019, 39 (02): : 196 - 203
  • [3] Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
    Yao, Xiaoxi
    Abraham, Neena S.
    Sangaralingham, Lindsey R.
    Bellolio, M. Fernanda
    McBane, Robert D.
    Shah, Nilay D.
    Noseworthy, Peter A.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2016, 5 (06):
  • [4] Effectiveness and Safety of Rivaroxaban versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Polypharmacy
    Mark J. Alberts
    Jinghua He
    Akshay Kharat
    Veronica Ashton
    American Journal of Cardiovascular Drugs, 2022, 22 : 425 - 436
  • [5] Effectiveness and Safety of Rivaroxaban versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Peripheral Artery Disease
    Martinez, Brandon K.
    Sood, Nitesh A.
    Bunz, Thomas J.
    Coleman, Craig I.
    STROKE, 2018, 49
  • [6] Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation
    Martinez, Brandon K.
    Sood, Nitesh A.
    Bunz, Thomas J.
    Coleman, Craig I.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2018, 7 (08):
  • [7] EFFECTIVENESS AND SAFETY OF APIXABAN, DABIGATRAN AND RIVAROXABAN VERSUS WARFARIN IN FRAIL PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION
    Coleman, Craig I.
    Turpie, Alexander
    Bunz, Thomas J.
    Sood, Nitesh
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) : 290 - 290
  • [8] Effectiveness and Safety of Rivaroxaban versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Polypharmacy
    Alberts, Mark J.
    He, Jinghua
    Kharat, Akshay
    Ashton, Veronica
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2022, 22 (04) : 425 - 436
  • [9] Effectiveness and safety of rivaroxaban versus warfarin among nonvalvular atrial fibrillation patients with obesity and diabetes
    Weir, Matthew R.
    Chen, Yen-Wen
    He, Jinghua
    Bookhart, Brahim
    Campbell, Alicia
    Ashton, Veronica
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2021, 35 (11)
  • [10] Effectiveness and safety of rivaroxaban versus warfarin in nonvalvular atrial fibrillation patients with coronary or peripheral artery disease
    Coleman, C. I.
    Sood, N.
    Bunz, T. J.
    Eriksson, D.
    Meinecke, A. -K.
    Baker, W. J.
    EUROPEAN HEART JOURNAL, 2019, 40 : 2982 - 2982
12345